EGFR and urinary bladder carcinoma: As luminal and basal bladder cancer subtypes are suspected to present a subtype specific overexpression of other well known drug targets like the FGFR, EGFR and ERBB gene families, the number of promising personalized therapy options rises for FOXM1 enriched MIBC [36].